Artemisone and artemiside control acute and reactivated toxoplasmosis in a murine model

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 10, 2009, Pages 4450-4456

  Dunay, Ildiko R ^a,c   Wing, Chi Chan ^b   Haynes, Richard K ^b   Sibley, L David ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Hong Kong)

^c UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMISIDE; ARTEMISININ; ARTEMISININ DERIVATIVE; ARTEMISONE; ARTESUNATE; SULFADIAZINE; UNCLASSIFIED DRUG;

ACUET TOXOPLASMOSIS; ACUTE TOXOPLASMOSIS; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE CONTROL; DISEASE COURSE; DRUG EFFICACY; DRUG INHIBITION; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PARASITE; PARASITE TRANSMISSION; PRIORITY JOURNAL; REACTIVATED TOXOPLASMOSIS; SURVIVAL; TOXOPLASMA GONDII; TOXOPLASMOSIS; TREATMENT OUTCOME;

ANIMALS; ANTIMALARIALS; ARTEMISININS; FEMALE; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; MOLECULAR STRUCTURE; TOXOPLASMOSIS, ANIMAL;

EID: 70349320504     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00502-09     Document Type: Article

References (41)

1. Ajzenberg, D., N. Cogné, L. Paris, M. H. Bessieres, P. Thulliez, D. Fillisetti, H. Pelloux, P. Marty, and M. L. Dardé. 2002. Genotype of 86 Toxoplasma gondii isolates associated with human congenital toxoplasmosis and correlation with clinical findings. J. Infect. Dis. 186:684-689.
2. Araujo, F. G., J. Huskinson, and J. S. Remington. 1991. Remarkable in vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against tachyzoites and tissue cysts of Toxoplasma gondii. Antimicrob. Agents Chemother. 35:293-299.
3. Ashley, E. A., and N. J. White. 2005. Artemisinin-based combinations. Curr. Opin. Infect. Dis. 18:531-536.
4. Baatz, H., A. Mirashahi, J. Puchta, H. Gumbel, and L. O. Hattenbach. 2006. Reactivation of toxoplasma retinochoroiditis under atovaquone therapy in an immunocompetent patient. Ocul. Immunol. Inflamm. 14:185-187.
5. Barragan, A., and L. D. Sibley. 2003. Migration of Toxoplasma gondii across biological barriers. Trends Microbiol. 11:426-430.
6. Brun-Pascaud, M., F. Chau, F. Derouin, and P. M. Girard. 1996. Lack of activity of artemether for prophylaxis and treatment of Toxoplasma gondii and Pneumocystis carinii infections in rat. Parasite 3:187-189.
7. Chirgwin, K., R. Hafner, C. Leport, J. Remington, J. Andersen, E. M. Bosler, C. Roque, N. Rajicic, V. McAuliffe, P. Morlat, D. T. Jayaweera, J. L. Vilde, B. J. Luft, et al. 2002. Randomized phase II trial of atovaquone with pyrimethamine and sulfadiazine treatment of toxoplasmic encephalitis in patients with acquired immunodeficiency syndrome: ATCC 237/ANRS 039 Study. Clin. Infect. Dis. 34:1243-1250.
8. D'Alessandro, S., M. Gelati, N. Basilico, E. A. Parati, R. K. Haynes, and D. Taramelli. 2007. Differential effects on angiogenesis of two antimalarial compounds, dihydroartemisinin and artemisone: implications for embryotoxicity. Toxicology 241:66-74. (Pubitemid 47599780)
9. Dubey, J. P. 2007. The life cycle of Toxoplasma gondii, p. 3-16. In J. W. Ajioka and D. Soldati (ed.), Toxoplasma: molecular and cellular biology. Horizon Bioscience, Norfolk, United Kingdom.
10. Dunay, I. R., M. M. Heimesaat, F. N. Bushrab, R. H. Muller, H. Stocker, K. Arasteh, M. Kurowski, R. Fitzner, K. Borner, and O. Liesenfeld. 2004. Atovaquone maintenance therapy prevents reactivation of toxopasmic encepahalitis in the murine model of reactivated toxoplasmosis. Antimicrob. Agents Chemother. 48:4848-4854.
11. Hall, S., K. A. Ryan, and D. Buxton. 2001. The epidemiology of toxoplasma infection, p. 58-124. In D. H. Joynson, and T. J. Wreghitt (ed.), Toxoplasmosis: a comprehensive clinical guide. Cambridge University Press, Cambridge, United Kingdom.
12. Haynes, R. K., H. O. Chan, M. K. Cheung, S. T. Chung, W. L. Lam, H. W. Tsang, A. Voerste, and I. D. Williams. 2003. Stereoselective preparation of 10-α and 10β-aryl derivatives of dihydroartemisinin. Eur. J. Org. Chem. 2003:2098-2114.
13. Haynes, R. K., B. Fugmann, J. Stetter, K. Rieckmann, H. D. Heilmann, H. W. Chan, M. K. Cheung, W. L. Lam, H. N. Wong, S. L. Croft, L. Vivas, L. Rattray, L. Stewart, W. Peters, B. L. Robinson, M. D. Edstien, B. M. Kotecka, D. E. Kyle, M. Gerisch, M. Radtke, G. Schmuck, W. Steinke, U. Wollborn, K. Schmeer, and A. S. Romer. 2006. Artemisone: a highly active antimalarial drug of the artemisinin class. Angew. Chem. Int. Ed. Engl. 45:1-8.
14. Haynes, R. K., and S. Krishna. 2004. Artemisinins: activities and actions. Microb. Infect. 6:1339-1346.
15. Howe, D. K., and L. D. Sibley. 1995. Toxoplasma gondii comprises three clonal lineages: correlation of parasite genotype with human disease. J. Infect. Dis. 172:1561-1566.
16. Jones, J. L., C. Muccioli, R. Belfort, Jr., G. N. Holland, J. M. Roberts, and C. Silveira. 2006. Recently acquired Toxoplasma gondii infection, Brazil. Emerg. Infect. Dis. 12:582-587.
17. Jones-Brando, L., J. D'Angelo, G. H. Posner, and R. H. Yolken. 2006. In vitro inhibition of Toxoplasma gondii by four new derivatives of artemisinin. Antimicrob. Agents Chemother. 50:4206-4208.
18. Khan, A., B. Fux, C. Su, J. P. Dubey, M. L. Darde, J. W. Ajioka, B. M. Rosenthal, and L. D. Sibley. 2007. Recent transcontinental sweep of Toxoplasma gondii driven by a single monomorphic chromosome. Proc. Natl. Acad. Sci. USA 104:14872-14877.
19. Krudsood, S., P. Wilairatana, K. Chalermrut, W. Leowattana, B. Voith, B. Hampel, and S. Looareesuwan. 2005. Artemifone, a new anti-malarial artemisinin derivative: open pilot trial to investigate the antiparasitic activity of bay 44-9585 in patients with uncomplicated P. falciparum malaria, p. 142. In Medicine and Health in the Tropics. Proceedings of the XVI International Congress for Tropical Medicine and Malaria. Marseilles, France.
20. Lehmann, T., P. L. Marcet, D. H. Graham, E. R. Dahl, and J. P. Dubey. 2006. Globalization and the population structure of Toxoplasma gondii. Proc. Natl. Acad. Sci. USA 103:11423-11428.
21. Liu, Q., F. Wei, S. Gao, L. Jiang, H. Lian, B. Yuan, Z. Yuan, Z. Xia, B. Liu, Z. Xu, and X. Q. Zhu. 2009. Toxoplasma gondii infection in pregnant women in China. Trans. R. Soc. Trop. Med. Hyg. 103:162-166.
22. McCabe, R. E. 2001. Antitoxoplasma chemotherapy, p. 319-359. In D. H. M. Joynson, and T. G. Wreghitt (ed.), Toxoplasmosis: a comprehensive clinical guide. Cambridge University Press, Cambridge, United Kingdom.
23. McLeod, R., K. Boyer, T. Karrison, K. Kasza, C. Swisher, N. Roizen, J. Jalbrzikowski, J. Remington, P. Heydemann, A. G. Noble, M. Mets, E. Holfels, S. Withers, P. Latkany, P. Meier, and Toxoplasmosis Study Group. 2006. Outcome of treatment for congenital toxoplasmosis, 1981-2004: the National Collaborative Chicago-Based, Congenital Toxoplasmosis Study. Clin. Infect. Dis. 42:1383-1394.
24. Megged, O., I. Shalit, I. Yaniv, J. Stein, S. Fisher, and I. Levy. 2008. Breakthrough cerebral toxoplasmosis in a patient receiving atovaquone prophylaxis after a hematopoietic stem cell transplant. Pediatr. Transplant. 12:902-905.
25. Montoya, J. G., and O. Liesenfled. 2004. Toxoplasmosis. Lancet 363:1965-1976.
26. Montoya, J. G., and J. S. Remington. 2008. Management of Toxoplasma gondii infection during pregnancy. Clin. Infect. Dis. 47:554-566.
27. Nagamune, K., S. N. J. Moreno, and L. D. Sibley. 2007. Artemisinin-resistant mutants of Toxoplasma gondii have altered calcium homeostasis. Antimicrob. Agents Chemother. 51:3816-3823.
28. Nagelschmitz, J., B. Voith, G. Wensing, A. Roemer, B. Fugmann, R. K. Haynes, B. M. Kotecka, K. H. Rieckmann, and M. D. Edstein. 2008. First assessment in humans of the safety, tolerability, pharmacokinetics, and ex vivo pharmacodynamic antimalarial activity of the new artemisinin derivative artemisone. Antimicrob. Agents Chemother. 52:3085-3091.
29. Petersen, E., and O. Liesenfeld. 2008. Clinical disease and diagnostics, p. 81-100. In L. M. Weiss and K. Kim (ed.), Toxoplasma gondii. The model Apicomplexan: perspectives and methods. Academic Press, Amsterdam, The Netherlands.
30. Saeij, J. P., J. P. Boyle, M. E. Grigg, G. Arrizabalaga, and J. C. Boothroyd. 2005. Bioluminescence imaging of Toxoplasma gondii infection in living mice reveals dramatic differences between strains. Infect. Immun. 73:695-702.
31. Schmuck, G., A. M. Klaus, F. Krotlinger, and F. W. Langewische. 2009. Developmental and reproductive toxicity studies on artemisone. Birth Defects Res. B 86:131-143.
32. Scholer, N., K. Krause, O. Kayser, R. H. Muller, K. Borner, H. Hahn, and O. Liesenfeld. 2001. Atovaquone nanosuspensions show excellent therapeutic effect in a new murine model of reactivated toxoplasmosis. Antimicrob. Agents Chemother. 45:1771-1779.
33. Seeber, F., and J. C. Boothroyd. 1996. Escherichia coli β-galactosidase as an in vitro and in vivo reporter enzyme and stable transfection marker in the intracellular protozoan parasite Toxoplasma gondii. Gene 169:39-45. (Pubitemid 26075695)
34. Silveira, C., R. Belfort, Jr., C. Muccioli, M. T. Abreu, M. C. Martins, C. Victora, R. B. Nussenblatt, and G. N. Holland. 2001. A follow-up study of Toxoplasma gondii infection in southern Brazil. Am. J. Ophthalmol. 131:351-354.
35. Steinke, W., B. Beckermann, H. Fischer, M. Gerisch, C. Kohlsdorfer, A. Römer, and G. Schmuck. 2005. Artemifone, a new anti-malarial artemisinin derivative: pharmacokinetics in rats and dogs, p. 143. In Medicine and Health in the Tropics. Proceedings of the XVI International Congress for Tropical Medicine and Malaria. Marseilles, France.
36. Suzuki, Y., F. K. Conley, and J. S. Remington. 1989. Importance of endogenous IFN-gamma for prevention of toxoplasmic encephalitis in mice. J. Immunol. 143:2045-2050. (Pubitemid 19241227)
37. Suzuki, Y., and K. Joh. 1994. Effect of the strain of Toxoplasma gondii on the development of toxoplasmic encephalitis in mice treated with antibody to interferon-gamma. Parasitol. Res. 80:125-130.
38. Suzuki, Y., H. Kang, S. F. Parmley, S. Lim, and D. Park. 2000. Induction of tumor necrosis factor- and inducible nitric oxide synthase fails to prevent toxoplasmic encephalitis in the absence of interferon-γ in genetically resistant BALB/c mice. Microb. Infect. 2:455-462.
39. Suzuki, Y., M. A. Orellana, R. D. Schreiber, and J. S. Remington. 1988. Interferon-γ: the major mediator of resistance against Toxoplasma gondii. Science 240:516-518.
40. Vivas, L., L. Rattray, L. B. Stewart, B. L. Robinson, B. Fugmann, R. K. Haynes, W. Peters, and S. L. Croft. 2007. Antimalarial efficacy and drug interactions of the novel semi-synthetic endoperoxide artemisone in vitro and in vivo. J. Antimicrob. Chemother. 59:658-665. (Pubitemid 47073399)
41. Wong, S., and J. S. Remington. 1994. Toxoplasmosis in pregnancy. Clin. Infect. Dis. 18:853-862.